NO20071259L - Ikke-kardiotoksiske farmasoytiske forbindelser. - Google Patents
Ikke-kardiotoksiske farmasoytiske forbindelser.Info
- Publication number
- NO20071259L NO20071259L NO20071259A NO20071259A NO20071259L NO 20071259 L NO20071259 L NO 20071259L NO 20071259 A NO20071259 A NO 20071259A NO 20071259 A NO20071259 A NO 20071259A NO 20071259 L NO20071259 L NO 20071259L
- Authority
- NO
- Norway
- Prior art keywords
- torsade
- pointes
- life
- pharmaceutical compositions
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/22—Amides of acids of phosphorus
- C07F9/24—Esteramides
- C07F9/2454—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic
- C07F9/2458—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic of aliphatic amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/22—Amides of acids of phosphorus
- C07F9/24—Esteramides
- C07F9/2454—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic
- C07F9/2462—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic of unsaturated acyclic amines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/22—Amides of acids of phosphorus
- C07F9/24—Esteramides
- C07F9/2454—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic
- C07F9/2466—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic of cycloaliphatic amines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/22—Amides of acids of phosphorus
- C07F9/24—Esteramides
- C07F9/2454—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic
- C07F9/247—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic of aromatic amines (N-C aromatic linkage)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/22—Amides of acids of phosphorus
- C07F9/24—Esteramides
- C07F9/2454—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic
- C07F9/2475—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic of aralkylamines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/5532—Seven-(or more) membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/5532—Seven-(or more) membered rings
- C07F9/5535—Seven-(or more) membered rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/572—Five-membered rings
- C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/58—Pyridine rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/59—Hydrogenated pyridine rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6503—Five-membered rings
- C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/650952—Six-membered rings having the nitrogen atoms in the positions 1 and 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
- C07F9/6533—Six-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
- C07F9/6544—Six-membered rings
- C07F9/6547—Six-membered rings condensed with carbocyclic rings or carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
- C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
- C07F9/65517—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring condensed with carbocyclic rings or carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
- C07F9/65525—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a seven-(or more) membered ring
- C07F9/65527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a seven-(or more) membered ring condensed with carbocyclic rings or carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms
- C07F9/655345—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms the sulfur atom being part of a five-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Abstract
Foreliggende oppfinnelse angår nye ikke-kardiotoksiske forbindelser og farmasøytiske preparater anvendelige ved behandling av en rekke lidelser omfattende behandling av depresjon, allergier, psykoser, kreft og gastrointestinal lidelser. Spesielt beskriver foreliggende oppfinnelse farmasøytiske preparater ved mitigat livstruende arrytmeias så som torsade de pointes. Torsade de pointes er et spesielt hjerteproblem forbundet med mange terapeutiske midler og er implisert som en mulig årsak til plutselig død, spesielt i de individer med en historie omfattende forstyrrelser av hjerterytme, myokardialt infarkt, medfødt repolarisering abnormaliteter og hjerterisikofaktorer så som hyperlipidemi og alder. Dette arytmi er en variant av paroksysmal ventrikulær tachycardia forbundet med en forlenget QTc intervall eller prominent U waves på ECG. Torsade de pointes er potensielt dødelig fordi det kan utvikle seg til ventrikulær fibrillering, livstruende arrytmeias eller presipitat plutselig død.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60069904P | 2004-08-11 | 2004-08-11 | |
US67354505P | 2005-04-21 | 2005-04-21 | |
PCT/US2005/028137 WO2006020573A2 (en) | 2004-08-11 | 2005-08-09 | Noncardiotoxic pharmaceutical compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20071259L true NO20071259L (no) | 2007-03-09 |
Family
ID=35908077
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20071259A NO20071259L (no) | 2004-08-11 | 2007-03-08 | Ikke-kardiotoksiske farmasoytiske forbindelser. |
Country Status (10)
Country | Link |
---|---|
US (1) | US8088918B2 (no) |
EP (1) | EP1778252A4 (no) |
JP (1) | JP2008509909A (no) |
AU (1) | AU2005273961A1 (no) |
CA (1) | CA2576530A1 (no) |
IL (1) | IL181229A0 (no) |
MX (1) | MX2007001713A (no) |
NO (1) | NO20071259L (no) |
SG (1) | SG169238A1 (no) |
WO (1) | WO2006020573A2 (no) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008536911A (ja) * | 2005-04-21 | 2008-09-11 | ターガンタ セラピュティクス,インコーポレイティド | ホスホン酸処理フルオロキノロン、その抗菌類似体および骨および関節感染の予防および治療方法 |
EP2077860B1 (en) | 2006-10-25 | 2014-04-09 | Ramot at Tel-Aviv University Ltd | Psychotropic agents having glutamate nmda activity |
RU2470013C2 (ru) * | 2007-04-12 | 2012-12-20 | НСАБ, Филиаль ау НьюроСёрч Свиден АБ, Сверийе | N-оксидные и/или ди-n-оксидные производные стабилизаторов/модуляторов рецепторов дофамина, проявляющие улучшенные профили сердечно-сосудистых побочных эффектов |
WO2013043744A2 (en) | 2011-09-21 | 2013-03-28 | Inception 1, Inc. | Tricyclic compounds useful as neurogenic and neuroprotective agents |
US9198916B1 (en) * | 2014-05-27 | 2015-12-01 | B&G Partners, Llc | Compounds and methods for treating tumors |
EP2998303B1 (en) | 2014-09-17 | 2018-06-13 | B & G Partners, LLC | Phenothiazine derivatives and methods for treating tumors |
KR102450287B1 (ko) * | 2016-09-29 | 2022-09-30 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 바이러스 감염 및 추가적인 질환의 치료를 위한 피리미딘 프로드러그 |
WO2023056102A1 (en) | 2021-10-01 | 2023-04-06 | ATAI Life Sciences AG | Novel prodrugs of mdma, mda, and derivatives thereof |
WO2023129958A2 (en) | 2021-12-28 | 2023-07-06 | ATAI Life Sciences AG | Nitric oxide releasing prodrugs of mda and mdma |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2832786A (en) * | 1956-02-27 | 1958-04-29 | Wm S Merrell Co | Phosphoramides |
BE575869A (no) * | 1958-02-20 | 1900-01-01 | ||
NL243963A (no) * | 1958-10-03 | |||
NL290813A (no) * | 1962-03-31 | |||
US4126442A (en) * | 1978-03-23 | 1978-11-21 | United States Borax & Chemical Corp. | O-Phosphoroamidophenylmorpholine compounds and use as herbicides |
FR2508442A1 (fr) * | 1981-06-30 | 1982-12-31 | Sanofi Sa | Procede de preparation d'ethylamines b-cyclo-substituees et produits ainsi obtenus |
NZ198115A (en) * | 1981-08-21 | 1985-05-31 | New Zealand Dev Finance | 9-anilinoacridines;pharmaceutical compositions |
US4824850A (en) * | 1982-05-18 | 1989-04-25 | University Of Florida | Brain-specific drug delivery |
US4584132A (en) * | 1983-08-09 | 1986-04-22 | Hoffmann-La Roche Inc. | 1-(N-phosphinylcarbamoyl) β-lactam antibacterial agents |
US5212291A (en) * | 1986-10-23 | 1993-05-18 | American Cyanamid Company | Anthracycline derivatives as solubilized pro-drugs |
US5070082A (en) * | 1986-10-23 | 1991-12-03 | American Cyanamid Company | Solubilized pro-drugs |
US5077283A (en) * | 1986-10-23 | 1991-12-31 | American Cyanamid Company | Solubilized imidazole pro-drugs |
US5116827A (en) * | 1986-10-23 | 1992-05-26 | American Cyanamid Company | Quinolinecarboxylic acid derivatives as solubilized pro-drugs |
ES2006099A6 (es) * | 1988-03-03 | 1989-04-01 | Investchemi S A | Procedimiento para la obtencion de hidrocloruro de ciprofloxacina monohidrato. |
EP0338372A3 (en) * | 1988-04-22 | 1991-10-09 | American Cyanamid Company | Solubilized pro-drugs |
CA2001203C (en) * | 1988-10-24 | 2001-02-13 | Thomas P. Demuth, Jr. | Novel antimicrobial dithiocarbamoyl quinolones |
US5328908A (en) * | 1988-10-24 | 1994-07-12 | Procter & Gamble Pharmaceuticals, Inc. | Antimicrobial quinolone thioureas |
RU1786037C (ru) * | 1991-05-05 | 1993-01-07 | Институт биоорганической химии и нефтехимии АН УССР | N-Замещенные фосфамиды, обладающие ювенильно-гормональной активностью |
US5334741A (en) * | 1992-07-20 | 1994-08-02 | Research Corporation Technologies, Inc. | Phosphorylation with monomeric metaphosphates |
US5646163A (en) * | 1992-10-30 | 1997-07-08 | The Procter & Gamble Company | Quinolone 5-(N-heterosubstituted amino) antimicrobials |
TW385308B (en) * | 1994-03-04 | 2000-03-21 | Merck & Co Inc | Prodrugs of morpholine tachykinin receptor antagonists |
CA2143143A1 (en) * | 1994-03-08 | 1995-09-09 | Toshihiko Tanaka | 3-phenylpyrrolidine derivatives |
JPH07300455A (ja) * | 1994-03-08 | 1995-11-14 | Mitsubishi Chem Corp | 3−フェニルピロリジン誘導体 |
US5688955A (en) * | 1996-03-08 | 1997-11-18 | Adolor Corporation | Kappa agonist compounds and pharmaceutical formulations thereof |
US5958905A (en) * | 1996-03-26 | 1999-09-28 | Texas Biotechnology Corporation | Phosphoramidates, phosphinic amides and related compounds and the use thereof to modulate the activity of endothelin |
US5807846A (en) * | 1996-11-14 | 1998-09-15 | Warner-Lambert Company | Phosphonamide ACAT inhibitors |
AU731586B2 (en) * | 1997-07-09 | 2001-04-05 | Merck Sharp & Dohme Corp. | Process for synthesizing carbapenem side chain intermediates |
US6214812B1 (en) * | 1998-04-02 | 2001-04-10 | Mbc Research, Inc. | Bisphosphonate conjugates and methods of making and using the same |
JP2000080094A (ja) * | 1998-07-02 | 2000-03-21 | Sankyo Co Ltd | 5員ヘテロアリ―ル化合物 |
WO2000006176A1 (en) * | 1998-07-31 | 2000-02-10 | Eli Lilly And Company | Amidophosphate derivatives |
EP2289521A3 (en) * | 1999-02-18 | 2011-10-05 | Arizona Board Of Regents | Compositions and methods for use in tergeting vascular destruction |
US7001926B2 (en) * | 2000-03-10 | 2006-02-21 | Oxigene, Inc. | Tubulin binding agents and corresponding prodrug constructs |
WO2001019794A2 (en) * | 1999-09-17 | 2001-03-22 | Baylor University | Indole-containing and combretastatin-related anti-mitotic and anti-tubulin polymerization agents |
EP1263763B1 (en) * | 2000-03-10 | 2007-07-25 | Baylor University | Tubulin binding ligands |
JP2004523480A (ja) * | 2000-08-22 | 2004-08-05 | ニュー リバー ファーマシューティカルズ, インコーポレイテッド | 活性作用物質送達系ならびに活性作用物質の保護および投与方法 |
US6746794B2 (en) * | 2001-06-12 | 2004-06-08 | Tech Drive, Inc | Thermal runaway inhibitors |
WO2004064728A2 (en) * | 2003-01-16 | 2004-08-05 | Paratek Pharmaceuticals, Inc. | Use of specific tetracycline compounds in therapy |
US20060205733A1 (en) * | 2004-08-26 | 2006-09-14 | Encysive Pharmaceuticals | Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof |
-
2005
- 2005-08-09 AU AU2005273961A patent/AU2005273961A1/en not_active Abandoned
- 2005-08-09 JP JP2007525709A patent/JP2008509909A/ja active Pending
- 2005-08-09 CA CA002576530A patent/CA2576530A1/en not_active Abandoned
- 2005-08-09 WO PCT/US2005/028137 patent/WO2006020573A2/en active Application Filing
- 2005-08-09 US US11/199,866 patent/US8088918B2/en not_active Expired - Fee Related
- 2005-08-09 MX MX2007001713A patent/MX2007001713A/es not_active Application Discontinuation
- 2005-08-09 EP EP05786819A patent/EP1778252A4/en not_active Withdrawn
- 2005-08-09 SG SG200905339-8A patent/SG169238A1/en unknown
-
2007
- 2007-02-08 IL IL181229A patent/IL181229A0/en unknown
- 2007-03-08 NO NO20071259A patent/NO20071259L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP1778252A4 (en) | 2010-01-27 |
IL181229A0 (en) | 2007-07-04 |
SG169238A1 (en) | 2011-03-30 |
US20060035863A1 (en) | 2006-02-16 |
MX2007001713A (es) | 2007-07-13 |
JP2008509909A (ja) | 2008-04-03 |
EP1778252A2 (en) | 2007-05-02 |
CA2576530A1 (en) | 2006-02-23 |
US8088918B2 (en) | 2012-01-03 |
WO2006020573A2 (en) | 2006-02-23 |
WO2006020573A3 (en) | 2009-04-16 |
AU2005273961A1 (en) | 2006-02-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20071259L (no) | Ikke-kardiotoksiske farmasoytiske forbindelser. | |
Sesselberg et al. | Ventricular arrhythmia storms in postinfarction patients with implantable defibrillators for primary prevention indications: a MADIT-II substudy | |
Murakoshi et al. | Epidemiology of arrhythmias and sudden cardiac death in Asia | |
Stiermaier et al. | Management of arrhythmias in patients with Takotsubo cardiomyopathy: Is the implantation of permanent devices necessary? | |
Hetland et al. | A novel ECG‐index for prediction of ventricular arrhythmias in patients after myocardial infarction | |
Imberti et al. | Clinical challenges in catecholaminergic polymorphic ventricular tachycardia | |
EA200702057A1 (ru) | Новые антиаритмические и применяемые при сердечной недостаточности лекарственные средства, которые направлены против "просачивания" рецептора рианодина (ryr2) | |
Wang et al. | Effect of pacing method on risk of sudden death after atrioventricular node ablation and pacemaker implantation in patients with atrial fibrillation | |
Francis et al. | Brugada syndrome | |
Aizawa et al. | Circadian pattern of fibrillatory events in non–Brugada-type idiopathic ventricular fibrillation with a focus on J waves | |
Hayashi et al. | Fragmented QRS predicts cardiovascular death of patients with structural heart disease and inducible ventricular tachyarrhythmia | |
Kukla et al. | Original article Inferior wall myocardial infarction with or without right ventricular involvement-treatment and in-hospital course | |
NO20070147L (no) | Nye oksabispidinforbindelser og deres anvendelse ved behandling av forstyrrelser i hjerterytmen | |
García-Niebla et al. | Interatrial block and takotsubo syndrome | |
Dickinson et al. | AB24-2: Statin therapy was associated with reduced atrial fibrillation and flutter in heart failure patients in SCD-HeFT | |
Sivagangabalan et al. | Antitachycardia pacing for very fast ventricular tachycardia and low-energy shock for ventricular arrhythmias in patients with implantable defibrillators | |
Benítez Ramos et al. | Electrocardiographic markers of appropriate implantable cardioverter-defibrillator therapy in young people with congenital heart diseases | |
Alizadeh-Ghavidel et al. | Amiodarone versus lidocaine for the prevention of reperfusion ventricular fibrillation: A randomized clinical trial | |
Bilik et al. | Unexpected guest: Atrial fibrillation due to electrical shock | |
Hai et al. | Slow heart rate predicts new occurrence of atrial fibrillation | |
Zang et al. | Evaluating common NOS1AP variants in patients with implantable cardioverter defibrillators for secondary prevention: evaluating SNPs in NOS1AP | |
Francis | Prevention of sudden cardiac death | |
Okabe et al. | Atrial Fibrillation and Atrial Flutter | |
Miyazaki | Silent takotsubo cardiomyopathy after cryoballoon ablation: Author’s reply | |
Mavrakis et al. | CRT37: The development of malignant ventricular arrhythmia in patients with ischemic cardiomyopathy and the prognostic significance of NT-PROBNP |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |